Acta Med. 2012, 55: 47-49
https://doi.org/10.14712/18059694.2015.75
Surgical Management of Severe Spontaneous Hemorrhage of the Abdominal Wall Complicating Acenocoumarol Treatment
References
1. P, Luceros AS, Meschengieser S, Bermejo E, Lazzari MA. INR variability in anticoagulation with acenocoumarol: is it useful for identifying patients at risk of bleeding and thrombosis? Haematologica 1999; 84: 753–4.
2. P, Luceros AS, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63: 192–6.
<https://doi.org/10.1002/(SICI)1096-8652(200004)63:4<192::AID-AJH5>3.0.CO;2-K>
3. MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin‑time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329: 696–702.
<https://doi.org/10.1056/NEJM199309023291005>
4. MP, Pan KT, Pealer KM. CT criteria for differentiating abdominal hemorrhage: anticoagulation or aortic aneurysm rupture? AJR Am J Roentgenol 2007; 188: 1324–30.
<https://doi.org/10.2214/AJR.05.1911>
5. R, Schoendorff G, Muñoz‑Guerra MF, Rodríguez‑Campo FJ, Naval‑Gías L, Sastre‑Pérez J. Upper airway obstruction by sublingual hematoma: a complication of anticoagulation therapy with acenocoumarol. Am J Otolaryngol 2006; 27: 129–32.
<https://doi.org/10.1016/j.amjoto.2005.07.013>
6. J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. Circulation 1994; 89: 1469–80.
<https://doi.org/10.1161/01.CIR.89.3.1469>
7. J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 2007; 53: 17–22.
<https://doi.org/10.4103/0022-3859.30322>
8. S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant‑related major hemorrhage. Arch Intern Med 2004; 164: 1557–60.
<https://doi.org/10.1001/archinte.164.14.1557>
9. M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471–6.
<https://doi.org/10.1182/blood-2007-11-123711>
10. V, Roldán V, Antón AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113: 4977–9.
<https://doi.org/10.1182/blood-2008-09-176222>
11. RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007; 32: 641–9.
<https://doi.org/10.1111/j.1365-2710.2007.00870.x>
12. K, Uzun O, Anadol AZ, Gök A. Surgical management of enoxaparin‑ and/ or warfarin‑induced massive retroperitoneal bleeding: report of a case and review of the literature. South Med J 2005; 98: 104–6.
<https://doi.org/10.1097/01.SMJ.0000145306.59008.4E>
13. A, Martínez M, Fernández A, et al. The effect of acenocoumarol on hemorheological parameters. Clin Hemorheol Microcirc 2001; 24: 111–5.
14. Z, Ruiz JR, Santiago C, Valle B, et al. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 2010; 5: e11210.
<https://doi.org/10.1371/journal.pone.0011210>
<PubMed>
15. PF, Petitjeans F, Lions C, Ould‑Ahmed M, Escarment J. Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. Am J Geriatr Pharmacother 2008; 6: 173–7.
<https://doi.org/10.1016/j.amjopharm.2008.07.004>
